- Conditions
- Neurogenic Orthostatic Hypotension
- Interventions
- Atomoxetine, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 2
- States / cities
- New York, New York • Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 128
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cognition in Schizophrenia
- Interventions
- Atomoxetine, Placebo
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- MPH (Concerta), MPH (Ritalin), Atomoxetine (ATO), Guanfacine (GFC)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 17,418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Titusville, New Jersey
- Conditions
- Alzheimer Disease
- Interventions
- atomoxetine hydrochloride, placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 3
- States / cities
- Sherman Oaks, California • Rochester, New York • Wichita Falls, Texas
- Conditions
- OSA
- Interventions
- AD109, Placebo
- Drug
- Lead sponsor
- Apnimed
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 646 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 65
- States / cities
- Tuscaloosa, Alabama • Mesa, Arizona • Phoenix, Arizona + 56 more
- Conditions
- Schizophrenia
- Interventions
- Clozapine augmented with atomoxetine up to 40 mg or placebo
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- ADHD
- Interventions
- ADHD medication, Placebo
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Atomoxetine, Placebo, Parent Training
- Drug · Behavioral
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 5 Years to 6 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 3
- States / cities
- Omaha, Nebraska • New York, New York • Durham, North Carolina
- Conditions
- Cocaine Dependence, Nicotine Dependence
- Interventions
- Progesterone, Placebo
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Attention Deficit Disorder With Hyperactivity, Cocaine-Related Disorders
- Interventions
- Atomoxetine
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Mixed salts of a single-entity amphetamine, Atomoxetine hydrochloride
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 19 Years to 25 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Posttraumatic Stress Disorder With Attention Defic
- Interventions
- Atomoxetine, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- OSA
- Interventions
- Atomoxetine 80 mg plus Oxybutynin 5 mg, Atomoxetine 80 MG, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Adult Attention Deficit Hyperactivity Disorder
- Interventions
- OPC-64005, Atomoxetine, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 26
- States / cities
- Beverly Hills, California • Garden Grove, California • San Diego, California + 20 more
- Conditions
- Attention Deficit Hyperactivity Disorder, Dyslexia
- Interventions
- Atomoxetine, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 10 Years to 16 Years
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 16
- States / cities
- Irvine, California • Palo Alto, California • San Francisco, California + 13 more
- Conditions
- Depressive Symptoms
- Interventions
- Atomoxetine Hydrochloride, Sertraline, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Alcohol Use Disorder
- Interventions
- Atomoxetine, Placebo
- Drug
- Lead sponsor
- Brown University
- Other
- Eligibility
- 14 Years to 20 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Obstructive Sleep Apnea, Down Syndrome
- Interventions
- Atomoxetine and oxybutynin (ato-oxy)
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Fetal Alcohol Syndrome, Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Atomoxetine
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Atomoxetine hydrochloride, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 445 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 27
- States / cities
- Los Angeles, California • Rolling Hills Est., California • Spring Valley, California + 24 more
- Conditions
- Attention Deficit Hyperactivity Disorder, Insomnia
- Interventions
- atomoxetine, placebo
- Drug
- Lead sponsor
- Rhode Island Hospital
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Traumatic Brain INjury
- Interventions
- atomoxetine, placebo
- Drug
- Lead sponsor
- Craig Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Englewood, Colorado
- Conditions
- Orthostatic Intolerance
- Interventions
- Atomoxetine, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Post Traumatic Stress Disorder, Attention Deficit Hyperactivity Disorder
- Interventions
- Atomoxetine 80 MG
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 20 Years to 60 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina